Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis - 12/05/18
Doi : 10.1016/j.jaad.2018.02.031
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD ⁎ 
Section of Dermatology, Division of General Pediatrics, The Children's Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
∗Correspondence to: Leslie Castelo-Soccio, MD, PhD, Division of Pediatrics, Section of Dermatology, The Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Wood Center 3rd Floor Dermatology, Room 3335, Philadelphia, Pennsylvania 19104Division of PediatricsSection of DermatologyThe Children's Hospital of Philadelphia3401 Civic Center BlvdWood Center 3rd Floor DermatologyRoom 3335PhiladelphiaPennsylvania19104
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| Reprints not available from the authors. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 78 - N° 6
P. 1207 - juin 2018 Retour au numéro
Article précédent
- Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B
- Deep Joshipura, Abdulaziz Alomran, Pedro Zancanaro, David Rosmarin
- Rapid improvement of prurigo nodularis with cyclosporine treatment
- Lauren E. Wiznia, Shields W. Callahan, David E. Cohen, Seth J. Orlow
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?